Multi-year Revenue GrowthSustained multi-year revenue growth demonstrates expanding commercial traction and market penetration. Durable top-line momentum supports scale economics, allows reinvestment in capacity or product development, and underpins medium-term competitiveness even if margins fluctuate.

Growing Equity BaseA steadily increasing shareholders' equity and healthy equity ratio create a durable capital cushion, improving solvency and capacity to fund growth internally. This strengthens resilience to downturns and reduces immediate dependency on external financing over the medium term.

Stable Operating MarginsRelatively stable EBIT and EBITDA margins imply the core chemical operations generate predictable operating profits and possess operational leverage. That stability supports sustained cash generation potential and competitive positioning despite volatility in net income.

Bears Say

Declining Net IncomeRecent declines in net income signal weakening bottom-line performance despite revenue gains. Persistent profit erosion reduces retained earnings, pressures return metrics and dividend capacity, and could restrict reinvestment or margin recovery without structural cost or pricing fixes.

Rising LeverageAn uptick in debt-to-equity increases financial risk and interest obligations, reducing balance-sheet flexibility. Higher leverage constrains the firm’s ability to fund capital projects internally, raises refinancing risk, and can magnify downside impact if earnings remain volatile.

Negative Free Cash FlowNegative free cash flow and weak conversion of net income into cash point to structural cash-generation stress. This limits internal funding for capex, debt reduction or dividends, forcing reliance on external financing or asset moves and increasing medium-term liquidity risk.

NGL Fine-Chem Ltd. News

NGL Fine-Chem Outlook Raised to Stable by Crisil

NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) has provided an announcement. NGL Fine-Chem Limited announced that Crisil Ratings has...

10d ago

NGL Fine-Chem Board Clears Q3 FY26 Results, Appoints New Company Secretary

NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) just unveiled an announcement. NGL Fine-Chem Ltd.’s board has approved the unaudited...

2M ago

NGL Fine-Chem Clears Q3 FY26 Results, Appoints New Compliance Head

An announcement from NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) is now available. NGL Fine-Chem Ltd. announced that its...

2M ago

NGL Fine-Chem Confirms SEBI-Compliant Dematerialisation of Securities for December Quarter

NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) has provided an update. NGL Fine-Chem Ltd. has informed the stock exchanges...

3M ago

NGLFINE FAQ

What was NGL Fine-Chem Ltd.’s price range in the past 12 months?

NGL Fine-Chem Ltd. lowest stock price was ₹985.05 and its highest was ₹2596.00 in the past 12 months.

What is NGL Fine-Chem Ltd.’s market cap?

NGL Fine-Chem Ltd.’s market cap is ₹13.51B.

When is NGL Fine-Chem Ltd.’s upcoming earnings report date?

NGL Fine-Chem Ltd.’s upcoming earnings report date is May 27, 2026 which is in 65 days.

How were NGL Fine-Chem Ltd.’s earnings last quarter?

NGL Fine-Chem Ltd. released its earnings results on Feb 03, 2026. The company reported ₹25.398 earnings per share for the quarter, beating the consensus estimate of N/A by ₹25.398.

Is NGL Fine-Chem Ltd. overvalued?

According to Wall Street analysts NGL Fine-Chem Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NGL Fine-Chem Ltd. pay dividends?

NGL Fine-Chem Ltd. pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.13%. See more information on NGL Fine-Chem Ltd. dividends here

What is NGL Fine-Chem Ltd.’s EPS estimate?

NGL Fine-Chem Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NGL Fine-Chem Ltd. have?

NGL Fine-Chem Ltd. has 6,178,024 shares outstanding.

What happened to NGL Fine-Chem Ltd.’s price movement after its last earnings report?

NGL Fine-Chem Ltd. reported an EPS of ₹25.398 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.203%.

Which hedge fund is a major shareholder of NGL Fine-Chem Ltd.?

Currently, no hedge funds are holding shares in IN:NGLFINE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NGL Fine-Chem Ltd.

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.